Moderna and CytomX Therapeutics, a drug developer focused on creating cancer therapies, have partnered in a licensing agreement that will use CytomX's Probody therapeutic platform in combination with Moderna's mRNA technologies to produce experimental mRNA-based therapies that are conditionally activated for a wide array of conditions. Moderna will pay CytomX $35 million as an upfront payment, and the latter will be eligible to gain up to $1.2 billion in potential payments for developmental, regulatory and commercial milestones in addition to tiered global net sales royalties.